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Abstract
Data from two studies of transgender women in Los Angeles County that used the same methodology and survey assess-
ment (Study 1: 1998–1999, N = 244; Study 2: 2015–2016, N = 271), compared structural determinants of health, HIV/STI 
prevalence, HIV risk behaviors, substance use, gender confirmation procedures, and perceived discrimination and harass-
ment/abuse across a 17-year time period. Findings demonstrated that participants in the latter study reported significantly 
higher access to healthcare insurance and prescription hormones. However, participants in the latter study also reported 
lower levels of income; and, elevated prevalence of homelessness, HIV and lifetime STIs, receptive condomless anal inter-
course with casual partner(s), and reported physical harassment/abuse. Given the timeframe of these results, these findings 
elucidate specific areas of transgender women’s health and risk profiles that improved or worsened across 17 years. While 
healthcare access has improved, transgender women continue to face significant barriers to good health, indicating the need 
for increased attention to this population.
Keywords Transgender women · Health disparities · HIV risk behaviors · Healthcare utilization
Introduction
Transgender women face numerous adverse health dis-
parities in comparison to cisgender individuals, including 
higher rates of substance use; HIV and STI prevalence, 
incidence and risk behaviors; and, mental health disorders 
including depression, anxiety and suicidality [1–5]. Due to 
structural barriers (i.e., laws and policies) and interpersonal 
stigmatization (e.g., prejudice, harassment, abuse) [6], 
transgender women are more likely than other adult popu-
lations to experience unemployment, homelessness, and to 
earn lower income [7–9], all of which are discrete predictors 
of poor health. The cyclical nature of these health dispari-
ties is perhaps most evident in the high rates of transgender 
women who engage in sex work [10–13]: forced out of legit-
imate economies due to discrimination, transgender women 
often turn to sex work to survive, which in turn puts them at 
increased risk for HIV and STIs, violence, and incarceration 
[10–12, 14].
Health disparities and significant structural and interper-
sonal barriers to good health have been well-documented 
among transgender women; however, no study has inves-
tigated how these health disparities and determinants have 
improved or worsened over time. The last decade saw major 
changes in the social, political, and medical context around 
transgender issues [15] such as HIV prevention and biomedi-
cal interventions including the availability of Pre-exposure 
Prophylaxis (PrEP) [16]; increased transgender visibility in 
the media and popular culture [17]; and transgender-specific 
policies such as “Bathroom Bills” making headline news 
[18]. Despite these cultural and medical shifts, it is unclear 
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what the impact of these changes, if any, is on the health 
of transgender communities. A search of longitudinal and 
comparison studies of transgender health finds that almost 
all were published after 2010 and utilized short-term fol-
low-up or comparison (i.e., less than 1–4 years) [19–21]. 
An incomplete understanding of how risk profiles and 
health outcomes among transgender women have or have 
not changed over longer periods of time limits the ability 
of public health professionals to implement targeted inter-
ventions focused on high-risk transgender populations. For 
instance, while there have been extensive efforts in the past 
decade to increase health research and implement tailored 
interventions for transgender women [22–27], the impact of 
these efforts remains unclear without data from comparison 
studies across time.
This study fills a much-needed gap in the literature as 
the first comparison study of transgender women’s health 
disparities, HIV risk behaviors, substance use, healthcare 
utilization, experiences of discrimination and HIV preva-
lence over two distal time points. Using data from two stud-
ies of transgender women in Los Angeles County (LAC) that 
used the same methodology and survey assessment (Study 
1: 1998–1999, N = 244; Study 2: 2015–2016, N = 271) we 
sought to compare how structural determinants of health 
(i.e., housing, healthcare insurance, income), HIV and STI 
prevalence, HIV risk behaviors, substance use, gender con-
firmation procedures, and perceived discrimination and har-
assment/abuse differed across a 17-year time period. The 
aim of this investigation was to understand how transgender 
health disparities in LAC have improved or worsened across 
multiple categories over time, so as to better inform health 
interventions focused on the unmet needs of transgender 
women.
Methods
Participants
Potential participants were deemed eligible to participate 
if they were 18 years of age or older; lived in LAC; and 
identified as a transgender woman or as a woman who 
was assigned the male sex at birth. Given the diversity in 
transgender populations over the 17 years since Study 1, 
and the aim to recruit moderate- and high-risk transgender 
women, the following eligibility was added to Study 2: 
Use of alcohol (any amount) or an illicit substance (includ-
ing non-medically prescribed marijuana) or unprotected 
anal intercourse (either insertive or receptive) in the past 
6 months. The added eligibility criterion was deemed nec-
essary to enroll a similar sample profile in Study 2 as was 
enrolled in Study 1. Due to the cultural shift in transgen-
der visibility over the 17 year period, without the added 
eligibility criterion no- and low-risk transgender women 
could enroll in the study. Yet, it was critical to enroll only 
moderate- and high-risk transgender women to address the 
aim of the study.
Procedures
Participants in Study 1 were recruited from February 1998 
to January 1999 and participants in Study 2 were recruited 
from July 2015 to September 2016. Potential participants 
for both studies were recruited via street- and venue-based 
outreach and from collaborating community-based organ-
izations that provided services to transgender women; 
most of the agencies were consistent between the two 
studies. All research assistants identified as a transgen-
der woman (four part-time research assistants for Study 
1 and two full-time research assistants for Study 2) and 
were highly trained on non-invasive outreach and recruit-
ment strategies, and how to maintain participant safety 
and confidentiality in the field. Following screening and 
consent, participants were administered The Los Angeles 
Transgender Health Survey (described below). In Study 1, 
the research assistants administered a paper assessment; 
whereas, in Study 2, participants received an audio com-
puter-assisted self-interview (ACASI) version of the same 
assessment. Both versions of the assessment took approxi-
mately 45 min to complete. Participants in Study 1 were 
compensated $15 for their time and effort after complet-
ing the assessment; participants in Study 2 were compen-
sated $50. Study 1 was approved by the Health Research 
Association Institutional Review Board and Study 2 was 
approved by the Friends Research Institute Institutional 
Review Board and the UCLA South Campus General Insti-
tutional Review Board. These Boards provided oversight 
for all study activities of the respective studies.
Assessment
The Los Angeles Transgender Health Survey
Developed by the first author and colleagues in 1997, in 
consultation with transgender women community mem-
bers, and updated as community needs have changed, the 
Los Angeles Transgender Health Survey consists of seven 
modules: screening, sociodemographic characteristics, 
health care access and medical history including HIV ser-
vices and hormone use/misuse, sexual behaviors (at all 
stages of gender transition) including HIV risk/protective 
behaviors, substance use, legal and psychosocial issues 
including stigma and discrimination, and HIV prevention.
2526 AIDS and Behavior (2018) 22:2524–2533
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Analytic Approach
Individual-level data from Study 1 were unavailable; how-
ever, the reported prevalence for each categorical variable 
was used to calculate count data. Fractional values of count 
data were rounded up to the greatest whole number and prev-
alence estimates were adjusted accordingly. Individual-level 
data for Study 2 were available and utilized to derive preva-
lence estimates. Chi square tests for categorical variables 
were conducted to test for differences in sociodemographic 
factors, structural health determinants, HIV and STI preva-
lence and risk behaviors, substance use, gender confirmation 
procedures, and perceived discrimination by study (Study 1: 
1998–1999 vs. Study 2: 2015–2016). To facilitate interpreta-
tion of results for greater than 2 × 2 contingency tables, two 
proportions z-tests were performed for each category level 
to compare observed proportions between Study 1 and Study 
2. SAS 9.4 was used to conduct analyses.
Results
Participant Sociodemographics
Weighted averages from the two samples (not presented in 
tables) demonstrated that participants were predominantly 
young (18–29 years = 47.2%), Hispanic/Latina (45.7%) or 
non-African American/Black/non-Hispanic/Latina (35.8%), 
heterosexual (75.2%), low income (< $1000/month = 66.9%), 
and had lower overall educational attainment (high school 
diploma/GED or less = 71.9%). Compared to the participants 
in Study 1, participants in Study 2 were slightly older, more 
likely to be African American/Black but less likely to be 
Non-Black/Non-Hispanic, and more likely to have lower 
income (p < 0.0001). There was no difference in reported 
sexual identification between the two studies (p = 0.869; 
Table 1).
Structural Determinants of Health: Housing Status, 
Healthcare Insurance, and Income Source
Compared to participants in Study 1, participants in Study 
2 were significantly more likely to report being homeless 
(4.1% vs. 14.8%, p < 0.0001; Table 1). Access to healthcare 
insurance was significantly higher in Study 2 compared to 
Study 1 (34.8% vs. 77.1%, p < 0.0001). Prevalence of partici-
pants with public healthcare insurance (i.e., MediCal, Medi-
care, Medicaid) increased substantially (17.6% vs. 56.5%), 
while participants with private healthcare insurance (i.e., 
CoveredCA, employer, HMO) decreased slightly (17.2% vs. 
12.2%). The weighted average of reported sex work as a 
main source of income in the past 6 months was 42.9%: par-
ticipants in Study 2 had a lower prevalence of reported sex 
work (36.2%) compared to participants in Study 1 (49.6%, 
p < 0.05).
HIV and STI Prevalence
HIV prevalence was higher in the Study 2 sample compared 
to Study 1 (22.1% vs. 35.4%, p < 0.0001; Table 1). Lifetime 
prevalence of STIs was also higher in Study 2 (p < 0.05). 
Prevalence of gonorrhea (13.1% vs. 24%, p < .05) and syphi-
lis (11.9% vs. 26.3%, p < 0.0001) both doubled between the 
two samples. Lifetime prevalence of Chlamydia had the 
highest magnitude change between samples, with prevalence 
eight-fold higher in Study 2 (2% vs. 17.7%, p < 0.0001). 
Lifetime prevalence of genital/rectal warts (7% vs. 9.2%) 
and genital herpes (4.1% vs. 5.9%) were slightly higher in 
the Study 2 sample compared to Study 1, but these differ-
ences were not significant.
HIV Risk Behaviors and Substance Use
The prevalence of self-reported engagement in receptive 
condomless anal intercourse (Table 2) did not differ sig-
nificantly between the two samples in overall Chi square 
analysis (p = 0.306). However, compared to Study 1, partici-
pants in Study 2 reported higher prevalence of condomless 
anal intercourse with every partner type: with any partner(s) 
(47.1% vs. 55.7%), main partner(s) (27.9% vs. 32.1%), cas-
ual partner(s) (19.6% vs. 32.8%), and exchange partner(s), 
i.e., individuals with whom they exchanged sex for things 
they needed such as money, drugs, shelter or food (13.9% 
vs. 18.8%). As well, inspection of z-test results demonstrates 
that proportion of participants engaging in condomless anal 
intercourse was significantly higher with casual partner(s) 
(p < 0.005) and marginally significantly higher with any 
partner (p = 0.06).
Prevalence of substance use (Table 2) in the past 6 months 
differed significantly between samples (p < 0.0001), but 
direction of change varied by substance. Participants in 
Study 2 were less likely to use alcohol (77.1% vs. 40.2%, 
p < 0.0001)), but more likely to use cannabis (38.4% vs. 
54.2%, p < 0.005). Prevalence of methamphetamine use 
did not change between samples (~ 27.5%). Participants in 
Study 2 were significantly less likely to use cocaine (25.0% 
vs. 10.0%, p < 0.0001) and crack cocaine (15.2% vs. 4.1%, 
p < 0.0001).
Hormone Use and Gender Confirmation Surgeries
As demonstrated in Table 2, non-medically prescribed/
non-medically monitored hormone use was significantly 
lower in Study 2 compared to Study 1 (36.1% vs. 9.9%; 
p < 0.0001). Prevalence of participants having had gender 
confirmation surgeries was also lower overall from Study 
2527AIDS and Behavior (2018) 22:2524–2533 
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Table 1  Participant 
sociodemographic 
characteristics and structural 
health determinants
a Multiple responses possible
*p value < 0.05
**p value < 0.005
***p value < 0.0005
Study 1: 1998–1999 
(N = 244)
Study 2: 2015–2016 
(N = 271)
Sig
n (%) n (%) Χ2 (p value)
z-test [p value]
Age 39.8 (< 0.0001)***
 18–29 132 54.1 109 40.2 9.38 [0.0022]**
 30–39 85 34.8 68 25.1 5.38 [0.0204]*
 40+ 27 11.1 94 34.7 38.55 [< 0.0001]***
Racial/ethnic identity 47.2 (< 0.0001)***
 Hispanic/Latina 120 49.2 114 42.1 2.34 [0.1259]
 African American/black 17 7.0 82 30.3 43.37 [< 0.0001]***
 Non-black/Non-hispanic 107 43.9 75 27.7 14.01 [0.0002]***
Sexual orientation 0.72 (0.869)
 Heterosexual/straight 187 76.6 199 73.7 0.54 [0.4611]
 Homosexual/gay/lesbian 22 15.3 28 10.4 0.13 [0.7230]
 Bisexual 14 5.7 17 6.3 0.01 [0.9446]
 Other/don’t know/refused 21 8.6 27 9.9 0.14 [0.7062]
Education level 15.9 (0.0003)***
 Less than high school/GED 114 46.7 99 36.5 5.09 [0.0241]*
 High school/GED 54 22.1 104 38.4 15.18 [< 0.0001]***
 Greater than high school/GED 76 31.1 68 25.1 2.05 [0.1526]
Income (past 30 days) 65.8 (< 0.0001)***
 < $1000 122 50.0 211 83.7 42.40 [< 0.0001]***
 $1000–$2999 98 40.2 28 11.1 60.23 [< 0.0001]***
 > $3000 24 9.8 13 5.2 4.16 [0.0413]*
HIV status 26.2 (< 0.0001)***
 HIV negative 189 77.5 159 58.7 19.83 [< 0.0001]***
 HIV positive 54 22.1 96 35.4 10.36 [0.0013]**
 Unknown/refused 1 .04 16 5.9 10.48 [0.0012]**
STI history (Lifetime)a 14.3 (0.0063)*
 Gonorrhea 32 13.1 65 24.0 9.23 [0.0024]**
 Syphilis 29 11.9 71 26.3 15.91 [< 0.0001]***
 Chlamydia 5 2.0 48 17.7 32.44 [< 0.0001]***
 Genital/rectal warts 17 7.0 25 9.2 0.60 [0.4392]
 Genital herpes 10 4.1 16 5.9 0.54 [0.4636]
Housing status 16.7 (< 0.0001)***
 Not homeless 234 95.9 231 85.2 –
 Homeless 10 4.1 40 14.8 –
Healthcare insurance 102.9 (< 0.0001)***
 Has healthcare insurance 85 34.8 209 77.1 92.00 [< 0.0001]***
 Does not have healthcare insurance 156 63.9 54 19.9 101.16 [< 0.0001]***
 Unknown/refused 3 1.2 8 3.0 1.09 [0.2961]
Type of healthcare insurance 29.2 (< 0.0001)***
 MediCal/medicare/medicaid 43 17.6 153 56.5 –
 Private/employer/HMO 42 17.2 33 12.2 –
 Sex work as main income source (past 
6 months)
9.5 (0.002)**
 Sex work as main source of income 121 49.6 98 36.2 –
Sex work not main source of income 123 50.4 173 63.8 –
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1 to Study 2 (p < 0.05). This significant difference was pri-
marily accounted for by the decrease between Study 1 and 
Study 2 of participants reporting rhinoplasty (18% vs. 6.3%, 
p < 0.0001).
Perceived Discrimination and Abuse
Chi square analysis found that overall perceived dis-
crimination was not significantly higher from Study 1 to 
Study 2 (p = 0.819; Table  3), but significant increases 
were observed in rates of hiring discrimination (47.1% 
vs. 64.2%, p < 0.0001), being fired from a job (29.1% vs. 
40.2%, p < 0.05), housing discrimination (29.9% vs. 42.2%, 
p < 0.005), and discrimination in accessing health services 
(13.1% vs. 21.4%, p < 0.05). Marginal significance was 
observed for increase in discrimination in accessing HIV 
prevention services (4.1% vs. 8.5%, p = 0.06). Reported life-
time harassment and abuse remained similarly high between 
samples, with a similar prevalence of reported verbal har-
assment/abuse (79.9% vs. 77.5%). Two proportions z-test 
demonstrated a significant increase in physical harassment/
abuse between Study 1 and Study 2 (47.1% vs. 56.8%, 
p < 0.05).
Discussion
To our knowledge, this study represents the first investi-
gation of how structural determinants of health and risk 
behaviors among transgender women improved or worsened 
across a substantial time period, i.e., close to two decades. 
Findings reported here utilized data from two similar sam-
ples of transgender women in LAC using the same outreach 
and recruitment strategies, the same survey assessment, 
and both studies conducted by the same investigator (first 
author). These findings highlight that transgender women 
continue to face substantial barriers to achieving optimum or 
even satisfactory health outcomes. Although participants in 
Study 2 reported greater access to healthcare insurance and 
utilization, these participants also reported lower income; 
elevated prevalence of homelessness, HIV and lifetime STIs, 
Table 2  HIV risk behaviors, 
substance use and gender 
confirmation procedures
a Multiple responses possible
*p value < 0.05
**p value < 0.005
***p value < 0.0005
Study 1: 1998–
1999 (N = 244)
Study 2: 2015–
2016 (N = 271)
Sig
n (%) n (%) Χ2 (p value)
z-test[p value]
Receptive condomless anal  intercoursea 2.4 (.306)
 With main partner(s) 68 27.9 87 32.1 .09 [0.3422]
 With casual partner(s) 48 19.6 89 32.8 10.74 [0.0011]**
 With exchange partner(s) 34 13.9 51 18.8 1.88 [0.1700]
 Any 115 47.1 151 55.7 3.46 [0.063]
Substance use (past 6 months)a 54.1 (< 0.0001)***
 Alcohol 188 77.1 109 40.2 69.83 [< 0.0001]***
 Cannabis 95 38.9 147 54.2 11.47 [0.0007]**
 Methamphetamine 68 27.9 74 27.3 0.002 [0.965]
 Cocaine 61 25.0 27 10.0 19.44 [< 0.0001]***
 Crack 37 15.2 11 4.1 17.44 [< 0.0001]***
 Poppers 24 9.8 14 5.2 3.44 [0.0635]
 Ecstasy 17 7.0 19 7.0 <.0001[1.00]
Hormone use (past 6 months) 64.3 (< 0.0001)***
 Non-prescribed 88 36.1 27 9.9 –
 Prescribed/medically monitored 54 22.1 132 48.7 –
Gender confirmation  surgerya 9.0 (0.029)*
 Breast augmentation 51 21.0 32 11.8 7.12 [0.0073]*
 Rhinoplasty 44 18.0 17 6.3 15.90 [< 0.0001]***
 Other facial surgery 15 6.1 8 3.0 2.37 [0.1237]
 Genital reconstruction (Vaginoplasty) 7 2.9 13 4.8 0.81 [0.3668]
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condomless anal intercourse, perceived discrimination and 
harassment/abuse; and a similar prevalence of methampheta-
mine use. Given the nature of these results across time, the 
findings presented here help to elucidate specific areas of 
transgender women’s health and risk profiles that improved 
or worsened across 17 years, thus allowing for targeted pub-
lic health interventions to assist in improving the health of 
transgender women.
Improved Determinants of Health between Study 1 
and Study 2
Healthcare Insurance and Healthcare Access
Prevalence of transgender women with access to health-
care insurance increased from just over one-third in Study 
1 to over three-fourths in Study 2. This increase was likely 
accounted for by a growth in access to public healthcare 
insurance (i.e., MediCal, Medicare, Medicaid). MediCal, 
California’s Medicaid program, saw a massive expansion 
under the Affordable Care Act in 2014 [28]. It is a notable 
commentary on the Affordable Care Act that some of the 
most vulnerable Californians, such as moderate- and high-
risk transgender women, were able to access public health-
care insurance.
Access to public healthcare insurance likely played a 
prominent role in increasing healthcare access between stud-
ies; changes in medically monitored hormone use between 
Study 1 and Study 2 highlighted positive signs that health-
care access among transgender women increased between 
the two studies. Nearly half of the sample in Study 2 reported 
access to prescribed or medically monitored hormones com-
pared to one-fifth of Study 1. Further, non-prescribed and 
non-medically monitored hormone use, including injectable 
hormones and “fillers,” decreased significantly, from over 
one-third (36.1%) in Study 1 to approximately one-in-ten 
(9.9%) in Study 2. This is a promising finding given the 
known adverse health effects of unsupervised hormone use, 
including blood clots, elevated liver enzymes, gallstones, 
decrease in hemoglobin, and depression [29, 30]. These find-
ings point to the fact that along with healthcare insurance, 
healthcare access substantially increased, which is encourag-
ing given the considerable health disparities faced by moder-
ate- and high-risk transgender women.
Worsened Health Determinants between Study 1 
and Study 2
Homelessness and Income
While the aforementioned improvements in healthcare insur-
ance and healthcare access were indeed promising, there 
remained numerous health determinants among transgender 
women that worsened over the 17 year period. Transgender 
women in both studies faced substantial structural (i.e., hous-
ing, healthcare insurance, income) and interpersonal (i.e., 
discrimination, harassment, abuse) barriers to good health. 
Compared to the Study 1 sample, prevalence of homeless-
ness in the Study 2 sample was nearly three-fold higher, and 
income was substantially lower, with 83.7% of participants 
reporting a monthly income of less than $1000. In addition 
to the marked decrease in income between studies, increased 
homelessness among Study 2 participants might be partially 
explained by the housing market in LAC: with surging rental 
prices and lack of subsidized housing vacancies, LAC’s gen-
eral homeless population has increased in the observed time 
Table 3  Perceived 
discrimination and abuse/
harassment
a Multiple responses possible
*p value < 0.05
**p value < 0.005
***p value < 0.0005
Study 1: 1998–1999 
(N = 244)
Study 2: 2015–2016 
(N = 271)
Sig
n (%) n (%) Χ2 (p value)
z-test [p value]
Perceived discrimination (Lifetime)a 1.5 (0.819)
 Job (hiring) 115 47.1 174 64.2 14.52 [0.0001]***
 Job (fired) 71 29.1 109 40.2 6.51 [0.0108]*
 Housing 73 29.9 115 42.4 8.15 [0.0043]**
 Health services 32 13.1 58 21.4 5.55 [0.0184]*
 HIV prevention services 10 4.1 23 8.5 3.42 [0.0642]
Abuse/harassment (Lifetime)a 1.9 (0.169)
 Verbal 195 79.9 210 77.5 0.32 [0.5732]
 Physical 115 47.1 154 56.8 4.46 [0.0348]*
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period [31]. There are limited data documenting the size 
of the homeless population in the 1990s: in 1994, the U.S. 
Department of Housing and Urban Development estimated 
that the size of the homeless population in LAC was between 
17,200 and 42,600 [32]. In 2016, the Los Angeles Homeless 
Services Authority estimated that the total size of the LAC 
homeless population was 46,874, which was 5.7% higher 
than the previous year [31]. The increased number of very 
low-income transgender women in Study 2, coupled with the 
LAC housing market likely explains the rise in homelessness 
between studies.
HIV and STI Prevalence and Sexual Risk Behaviors
HIV prevalence and lifetime prevalence of STIs (i.e., gon-
orrhea, syphilis, Chlamydia) increased significantly from 
Study 1 to Study 2. Furthermore, compared to Study 1, 
Study 2 evidenced elevated rates of receptive condomless 
anal intercourse with every partner type, including main 
partner(s), casual partner(s), and exchange partner(s). 
Engagement in condomless anal intercourse was signifi-
cantly higher with casual partner(s) (p < 0.005) and margin-
ally significantly higher with any partner (p = 0.06). These 
results highlight that sexual risk behaviors among transgen-
der women remain a key barrier to adequate prevention of 
HIV and STIs. As of the last available data in 2011, the 
LAC Department of Public Health, Division of HIV and 
STD Programs (DHSP) managed over 200 contracts with 65 
community-based organizations and ten county departments 
dedicated to HIV and STI prevention, testing, and services 
[33]. While HIV incidence among other adult populations 
in LAC and among MSM have decreased, STI rates have 
increased over the past decade [34]. These findings and cur-
rently available data from DHSP demonstrate that transgen-
der women report higher prevalence of HIV and STIs [35].
During the Study 1 years, HIV prevention funding for 
transgender individuals was not a separate identified popu-
lation and these services were funded under “gay men.” By 
the Study 2 years, DHSP was allocating $1,392,000 specifi-
cally to HIV prevention services for transgender individuals 
(personal communication via email, 23 June 2017, DHSP). 
However, the increase in HIV and STI prevalence and sex-
ual risk behaviors across samples highlights that, despite 
identifying transgender individuals as a funding priority 
and increased funding efforts, HIV, STIs, and sexual risk 
behaviors are both highly prevalent and difficult to prevent 
among transgender women. HIV and STI prevention efforts 
targeting moderate- and high-risk transgender women must 
take into account the numerous structural barriers faced by 
the population, and ensure that HIV and STI prevention 
efforts consider and target this difficult-to-reach population. 
For example, while Pre-exposure Prophylaxis (PrEP) is an 
effective biomedical HIV prevention strategy, the social and 
structural barriers that transgender women experience are 
associated with limited PrEP adherence [36, 37].
Substance Use
Prior studies have demonstrated the associations between 
substance use and HIV and STI risk behaviors among 
transgender women [38–41]. The current study found mixed 
results regarding substance use among transgender women. 
Compared to participants in Study 1, transgender women 
in Study 2 were less likely to drink alcohol, but more likely 
to use marijuana, both of which have been linked to con-
domless anal intercourse and HIV risk among transgender 
women [2, 42]. The higher rate of reported marijuana use 
is most likely a result in the policy shift related to medical 
marijuana in LAC, which contributed to increased availabil-
ity and public acceptance of marijuana use.
Furthermore, methamphetamine use remained high and 
stable across both studies, with approximately one-fourth 
of both samples reporting methamphetamine use in the past 
6 months; a troubling finding given the strong association 
between methamphetamine use and HIV sexual risk behav-
iors across numerous samples including transgender women 
[38, 43–45]. It is interesting to note that the consistently high 
rate of methamphetamine use is very similar to that found 
among samples of men who have sex with men in LAC, 
with approximately one-quarter of both populations report-
ing methamphetamine use [46]. Results from the current 
study indicate that high rates of substance use have persisted 
among transgender women in LAC, elucidating that HIV 
prevention efforts must target multiple levels of risk includ-
ing both sexual risk and substance use behaviors.
Discrimination, Harassment and Abuse
Compared to Study 1, transgender women in Study 2 expe-
rienced similar or higher lifetime rates of discrimination, 
harassment and abuse in every category surveyed. Life-
time housing discrimination and perceived employment 
discrimination due to participants’ transgender identity, 
or presentation, significantly increased, with over half of 
participants in Study 2 reporting some form of discrimina-
tion in either category. Transgender women in both studies 
reported severely high prevalence of verbal and physical 
harassment and abuse. Verbal harassment and abuse was 
reported by over three-quarters of participants in both stud-
ies, and more than half of the Study 2 participants reported 
experiencing physical harassment and abuse, a significant 
increase from Study 1. Among transgender women, experi-
ences of harassment and abuse are associated with anxiety, 
depression, PTSD, and suicidality [47–50]. These mental 
health correlates have been reported as significant barriers 
to employment and general functioning among transgender 
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individuals [6, 51]; thus, placing transgender individuals at 
increased risk of poverty [3, 8] and its associated detrimental 
health consequences. Given these results, the cyclical and 
syndemic nature of structural and interpersonal barriers to 
adequate health and wellbeing among transgender women 
is immense.
Reported discrimination in access to healthcare (includ-
ing refusal of care) significantly increased from 13.1% in 
Study 1 to 21.4% in Study 2 (p < 0.05). Across numerous 
studies of transgender women, discrimination in access-
ing healthcare services has been linked to healthcare delay 
and avoidance and overall worse health outcomes, includ-
ing lack of preventative healthcare [52, 53]. While the 
aforementioned increase in access to healthcare insurance 
in Study 2 was a promising finding, the concurrent higher 
prevalence of reported healthcare discrimination, as well as 
the decrease in gender-related surgeries, with the exception 
of genital reconstruction (i.e., vaginoplasty), highlighted the 
continued need for transgender-specific clinical and cultural 
competency trainings for healthcare providers. Additionally, 
with increased coverage of gender confirmation surgeries 
under the Affordable Care Act, the visibility of transgender 
persons in healthcare settings will simultaneously increase, 
further emphasizing the need for transgender-competent 
healthcare.
Limitations
As individual-level data from Study 1 were unavailable, dif-
ferences between groups could only be measured utilizing 
count data, which led to the inability to conduct more robust, 
multivariate analyses. Although the two samples had some 
consistency regarding sociodemographic characteristics, 
data were not longitudinal, both studies used convenience 
sampling, and any significant differences between samples 
may be as a result of demographic or sampling differences, 
or the added eligibility criterion in Study 2, rather than 
true differences in health and risk behaviors. Furthermore, 
measures of health service utilization other than medi-
cally monitored hormone use were not collected; therefore, 
we cannot make any inferences regarding how structural, 
interpersonal and risk behavior differences across samples 
affected access to healthcare among the samples. These data 
were limited in the self-reported nature of the survey (e.g., 
potential recall bias and social desirability bias in Study 1) 
and sampling bias given the highly stigmatized and hard-
to-reach nature of the population. An important limitation 
of both studies is that data were collected in LAC and may 
not be representative of transgender women in other regions 
of the U.S. Additionally, some participants were recruited 
through collaborating community-based organizations and; 
therefore, their data may not be representative of transgen-
der women who do not access social service agencies. As 
well, the high-risk nature of the sample makes these findings 
unlikely to be generalizable to transgender women who are 
less vulnerable than the participants in this study. Finally, 
while we can draw inferences about the effects of cultural, 
medical, and social shifts (e.g., Affordable Care Act) on dif-
ferences between study populations, future studies should 
attempt to examine longitudinal correlates between health 
determinants and policy/social/cultural changes affecting 
transgender women. Nevertheless, these findings represent 
the only long-term comparison data of transgender women 
and, therefore, provide an important comparison of how 
structural determinants of health, HIV and STI prevalence, 
HIV risk behaviors and substance use, gender confirmation 
procedures, and perceived discrimination and harassment/
abuse have improved or worsened over 17 years in LAC.
Conclusions
Findings presented here shed light on the numerous issues 
still faced by transgender women 17 years after the initial 
study, particularly homelessness, low education and income, 
HIV and STI risk, substance use, and perceived discrimina-
tion and harassment/abuse. The marked increase in access 
to healthcare insurance coupled with prescribed and medi-
cally monitored hormones highlights the positive impact of 
government-funded healthcare insurance programs for this 
vulnerable population. However, these findings must be 
tempered against the concurrent increase in reported preva-
lence of perceived healthcare discrimination. To improve 
transgender women’s healthcare outcomes, public health 
professionals must be trained and culturally competent to 
work with transgender women, and strive to implement 
health-related interventions that are specifically tailored to 
address the immense structural and interpersonal barriers 
faced by this population.
Acknowledgements The authors would like to acknowledge the work 
of the research assistants from both Study 1 and Study 2 and their dedi-
cation to serve their community, and the participants in both studies.
Funding Study 1 was supported by the California HIV/AIDS Research 
Program (formerly University of California Universitywide AIDS 
Research Program) Grant #PC97-LAC-012L and Study 2 was sup-
ported by the National Institute on Drug Abuse, Grant #R21DA037816. 
Dr. Reback acknowledges additional support from the National Institute 
of Mental Health (P30 MH58107). Ms. Clark acknowledges funding 
support from the UCLA Graduate Division and UCLA Fielding School 
of Public Health (Fellowship in Epidemiology, 2016–2017). Dr. Hol-
loway acknowledges funding support from the California HIV/AIDS 
Research Program (RP15-LA-007).
2532 AIDS and Behavior (2018) 22:2524–2533
1 3
Compliance with Ethical Standards 
Conflict of interest The authors declare no conflicts of interest.
Ethical Approval All procedures in the study involving human partici-
pants were in accordance with the ethical standards of the institutional 
research committee and with the 1964 Helsinki declaration and its later 
amendments or comparable standards.
Informed Consent Written informed consent was obtained from all 
participants.
References
 1. Bockting WO, Miner MH, Swinburne Romine RE, Hamilton A, 
Coleman E. Stigma, mental health, and resilience in an online 
sample of the US transgender population. Am J Public Health. 
2013;103(5):943–51.
 2. Clements-Nolle K, Marx R, Guzman R, Katz M. HIV preva-
lence, risk behaviors, health care use, and mental health status of 
transgender persons: implications for public health intervention. 
Am J Public Health. 2001;91(6):915.
 3. Grant JM, Mottet L, Tanis JE, Harrison J, Herman J, Keisling 
M. Injustice at every turn: a report of the national transgender 
discrimination survey: National Center for Transgender Equality. 
2011. http://www.theta skfor ce.org/stati c_html/downl oads/repor 
ts/repor ts/ntds_full.pdf. Accessed 20 Apr 2017.
 4. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prev-
alence and risk behaviors of transgender persons in the United 
States: a systematic review. AIDS Behav. 2008;12(1):1–17.
 5. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi 
MA. The Report of the 2015 U.S. Transgender Survey. National 
Center for Transgender Equality. 2016. http://www.trans equal ity.
org/sites /defau lt/files /docs/usts/USTS%20Ful l%20Rep ort%20
-%20FIN AL%201.6.17.pdf. Accessed 11 May 2017.
 6. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma 
and health: a critical review of stigma determinants, mechanisms, 
and interventions. Soc Sci Med. 2015;147:222–31.
 7. Addis S, Davies M, Greene G, MacBride-Stewart S, Shepherd M. 
The health, social care and housing needs of lesbian, gay, bisexual 
and transgender older people: a review of the literature. Health 
Soc Care Community. 2009;17(6):647–58.
 8. Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of 
transgender-related discrimination and implications for health: 
results from the Virginia Transgender Health Initiative Study. Am 
J Public Health. 2013;103(10):1820–9.
 9. Fletcher JB, Kisler KA, Reback CJ. Housing status and HIV risk 
behaviors among transgender women in Los Angeles. Arch Sex 
Behav. 2014;43(8):1651–61.
 10. Hwahng SJ, Nuttbrock L. Sex workers, fem queens, and cross-
dressers: differential marginalizations and HIV vulnerabilities 
among three ethnocultural male-to-female transgender commu-
nities in New York City. Sex Res Soc Policy. 2007;4(4):36–59.
 11. Kurtz SP, Surratt HL, Kiley MC, Inciardi JA. Barriers to health 
and social services for street-based sex workers. J Health Care 
Poor Underserved. 2005;16(2):345–61.
 12. Poteat T, Wirtz AL, Radix A, et  al. HIV risk and preven-
tive interventions in transgender women sex workers. Lancet. 
2015;385(9964):274–86.
 13. Sausa LA, Keatley J, Operario D. Perceived risks and benefits of 
sex work among transgender women of color in San Francisco. 
Arch Sex Behav. 2007;36(6):768–77.
 14. Nadal K, Vargas V, Meterko V, Hamit S, McLean K, Paludi M. 
Transgender female sex workers: personal perspectives, gender 
identity development, and psychological processes. In: Paludi 
M, editor. Managing diversity in today’s workplace Strategies 
for employees and employers. Santa Barbara: Praeger; 2012. p. 
123–53.
 15. MacCarthy S, Reisner SL, Nunn A, Perez-Brumer A, Operario D. 
The time is now: attention increases to transgender health in the 
United States but scientific knowledge gaps remain. LGBT Health. 
2015;2(4):287–91.
 16. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, 
Follansbee S, et al. No new HIV infections with increasing use of 
HIV preexposure prophylaxis in a clinical practice setting. Clin 
Infect Dis. 2015;61(10):1601–3.
 17. Stulberg L. The Perils and Possibilities of Transgender Visibil-
ity.2014. The Huffington Post, April, 4.
 18. Graham DA. What’s Behind the New Wave of Transgender ‘Bath-
room Bills.’ 2017. The Atlantic.
 19. Birkett M, Newcomb ME, Mustanski B. Does it get better? A 
longitudinal analysis of psychological distress and victimization 
in lesbian, gay, bisexual, transgender, and questioning youth. J 
Adolesc Health. 2015;56(3):280–5.
 20. Mustanski B, Liu RT. A longitudinal study of predictors of sui-
cide attempts among lesbian, gay, bisexual, and transgender youth. 
Arch Sex Behav. 2013;42(3):437–48.
 21. Newcomb ME, Heinz AJ, Mustanski B. Examining risk and 
protective factors for alcohol use in lesbian, gay, bisexual, and 
transgender youth: a longitudinal multilevel analysis. J Stud Alco-
hol Drugs. 2012;73(5):783–93.
 22. Garofalo R, Johnson AK, Kuhns LM, Cotton C, Joseph H, Mar-
golis A. Life skills: evaluation of a theory-driven behavioral HIV 
prevention intervention for young transgender women. J Urban 
Health. 2012;89(3):419–31.
 23. Graham R, Berkowitz B, Blum R, et al. The health of lesbian, 
gay, bisexual, and transgender people: Building a foundation for 
better understanding. 2011. https ://www.ncbi.nlm.nih.gov/books 
/NBK64 795/. Accessed 20 Apr 2017.
 24. Nemoto T, Operario D, Keatley J, Nguyen H, Sugano E. Promot-
ing health for transgender women: transgender Resources and 
Neighborhood Space (TRANS) program in San Francisco. Am J 
Public Health. 2005;95(3):382–4.
 25. Reback CJ, Lombardi E. HIV risk behaviors of male-to-female 
transgenders in a community-based harm reduction program. In: 
Bockting W, Kirk S, editors. Transgender and HIV: risks, preven-
tion, and care. New York: The Haworth Press; 2001. p. 59–68.
 26. Reback CJ, Shoptaw S, Downing MJ. Prevention case manage-
ment improves socioeconomic standing and reduces symptoms of 
psychological and emotional distress among transgender women. 
AIDS Care. 2012;24(9):1136–44.
 27. Rebchook G, Keatley J, Contreras R, et al. The transgender women 
of color initiative: implementing and evaluating innovative inter-
ventions to enhance engagement and retention in HIV care. Am J 
Public Health. 2017;107(2):224–9.
 28. California Health Care Foundation. Medi-Cal facts and figures: 
a program transforms. 2013. http://www.chcf.org/publi catio 
ns/2013/05/medic al-facts -figur es. Accessed 11 May 2017.
 29. Asscheman H, T’Sjoen G, Lemaire A, et al. Venous thrombo-
embolism as a complication of cross-sex hormone treatment 
of male-to-female transsexual subjects: a review. Andrologia. 
2014;46(7):791–5.
 30. Moore E, Wisniewski A, Dobs A. Endocrine treatment of trans-
sexual people: a review of treatment regimens, outcomes, and 
adverse effects. J Clin Endocrinol Metab. 2003;88(8):3467–73.
 31. Los Angeles Homeless Services Authority. 2016 Homeless Count 
Results. 2016. https ://docum ents.lahsa .org/Plann ing/homel essco 
unt/2016/facts heet/2016-HC-Resul ts.pdf. Accessed 11 May 2017.
2533AIDS and Behavior (2018) 22:2524–2533 
1 3
 32. U.S. Department of Housing and Urban Development. Citizen’s 
Summary: Los Angeles. 1994. https ://archi ves.hud.gov/repor ts/
plan/ca/losan gca.html. Accessed 20 Apr 2017.
 33. Fielding JE, Harding C, Perez MJ, et al. Annual HIV Testing 
Report. 2011. http://publi cheal th.lacou nty.gov/dhsp/Repor ts/HIV/
HIVTe sting Servi cesAn nualR eport 2011.pdf. Accessed 05 June 
2017.
 34. Division of HIV and STD Programs (DHSP), County of Los 
Angeles Public Health. Summary of LACDPH DHSP 2014 
Annual HIV/STD Surveillance Report. 2016. http://publi cheal 
th.lacou nty.gov/dhsp/Repor ts/HIV-STDsu rveil lance Repor t2014 
.pdf. Accessed 05 June 2017.
 35. Division of HIV and STD Programs (DHSP), County of Los 
Angeles Public Health. 2013 Sexually Transmitted Diseases Fact 
Sheet. 2015. http://www.publi cheal th.lacou nty.gov/dhsp/docs/
STDEp iFact Sheet %20Mar ch201 5.pdf. Accessed 05 June 2017.
 36. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure 
prophylaxis in transgender women: a subgroup analysis of the 
iPrEx trial. Lancet HIV. 2015;2(12):e512–9.
 37. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Wein-
berger CL. From efficacy to effectiveness: facilitators and barriers 
to PrEP acceptability and motivations for adherence among MSM 
and transgender women in New York City. AIDS Patient Care 
STDS. 2013;27(4):248–54.
 38. Reback CJ, Fletcher JB. HIV prevalence, substance use, and sex-
ual risk behaviors among transgender women recruited through 
outreach. AIDS Behav. 2014;18(7):1359–67.
 39. Reback CJ, Lombardi EL, Simon PA, Frye DM. HIV seropreva-
lence and risk behaviors among transgendered women who 
exchange sex in comparison with those who do not. J Psychol 
Human Sex. 2005;17(1–2):5–22.
 40. Shoptaw S, Reback CJ. Associations between methamphetamine 
use and HIV among men who have sex with men: a model for 
guiding public policy. J Urban Health. 2006;83(6):1151–7.
 41. Vosburgh HW, Mansergh G, Sullivan PS, Purcell DW. A review 
of the literature on event-level substance use and sexual risk 
behavior among men who have sex with men. AIDS Behav. 
2012;16(6):1394–410.
 42. Garofalo R, Osmer E, Sullivan C, Doll M, Harper G. Environmen-
tal, psychosocial, and individual correlates of HIV risk in ethnic 
minority male-to-female transgender youth. J HIV AIDS Prev 
Child Youth. 2007;7(2):89–104.
 43. Colfax G, Shoptaw S. The methamphetamine epidemic: implica-
tions for HIV prevention and treatment. Curr HIV/AIDS Rep. 
2005;2(4):194–9.
 44. Marshall BD, Wood E, Shoveller JA, Patterson TL, Montaner JS, 
Kerr T. Pathways to HIV risk and vulnerability among lesbian, 
gay, bisexual, and transgendered methamphetamine users: a multi-
cohort gender-based analysis. BMC Public Health. 2011;11(1):20.
 45. Plankey MW, Ostrow DG, Stall R, et al. The relationship between 
methamphetamine and popper use and risk of HIV seroconversion 
in the multicenter AIDS cohort study. J Acquir Immune Defic 
Syndr. 2007;45(1):85.
 46. Reback CJ, Shoptaw S, Grella CE. Methamphetamine use trends 
among street-recruited gay and bisexual males, from 1999 to 
2007. J Urban Health. 2008;85(6):874.
 47. Factor RJ, Rothblum ED. A study of transgender adults and 
their non-transgender siblings on demographic characteristics, 
social support, and experiences of violence. J LGBT Health Res. 
2008;3(3):11–30.
 48. Kussin-Shoptaw AL, Fletcher JB, Reback CJ. Physical and/
or sexual abuse is associated with increased psychological and 
emotional distress among transgender women. LGBT Health. 
2017;4(4):268–74.
 49. Lombardi EL, Wilchins RA, Priesing D, Malouf D. Gender vio-
lence: transgender experiences with violence and discrimination. 
J Homosex. 2002;42(1):89–101.
 50. Nemoto T, Bödeker B, Iwamoto M. Social support, exposure to 
violence and transphobia, and correlates of depression among 
male-to-female transgender women with a history of sex work. 
Am J Public Health. 2011;101(10):1980–8.
 51. Mizock L, Mueser KT. Employment, mental health, internalized 
stigma, and coping with transphobia among transgender individu-
als. Psychol Sex Orientat Gend Divers. 2014;1(2):146.
 52. Jaffee KD, Shires DA, Stroumsa D. Discrimination and delayed 
health care among transgender women and men: implications for 
improving medical education and health care delivery. Med Care. 
2016;54(11):1010–6.
 53. Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barri-
ers to care, and hormone usage among male-to-female transgender 
persons in New York City. Am J Public Health. 2009;99(4):713–9.
